Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):ONLS
АТХ:L.01 Antineoplastic agents
Pharmacodynamics:Selective blocker of interleukin (IL-1) receptors. Anakinra is a non-glycosylated recombinant human antagonist of IL-1 receptors, interferes with the binding of IL-1 to the receptor. It is used in the treatment of rheumatoid arthritis, a systemic autoimmune disease characterized by chronic polyarticular synovial inflammation caused by excessive production of pro-inflammatory factors by T cells, in particular interleukin-1.
Pharmacokinetics:The half-life is 12-14 hours. Metabolism in the liver, elimination with urine.
Indications:It is used as a symptomatic agent for severe rheumatoid arthritis in conjunction with basic drugs, except TNF-inhibitors.
XIII.M05-M14.M05.9 Seropositive rheumatoid arthritis, unspecified
XIII.M05-M14.M06.9 Rheumatoid arthritis, unspecified
XIII.M05-M14.M06.0 Seronegative rheumatoid arthritis
XIII.M05-M14.M05.3 Rheumatoid arthritis with involvement of other organs and systems
Contraindications:Acute infectious processes.
The state of immunodeficiency.
Individual intolerance.
Carefully:It is used with caution for patients with chronic infectious diseases.
Pregnancy and lactation:Pregnancy and lactation: recommendations for Food and Drug Administration (US Food and Drug Administration) - not specified. To use is not recommended.
Dosing and Administration:Subcutaneous injections in the region of the thigh or abdomen once a day in an amount of 100 mg.
The highest daily dose: 100 mg.
The highest single dose: 100 mg.
Side effects:Hyperemia of the skin, tenderness in the area of injection. For treatment, steroid ointments are used.
Allergic reactions.
Overdose:It is possible with simultaneous application of anakira and TNF-inhibitors: leukopenia, acute infectious diseases of the respiratory tract and gastrointestinal tract.
It is recommended that the drug be temporarily discontinued until the foci of infection are completely sanitized.
Interaction:Strengthens the action TNF-inhibitors, non-steroidal and steroidal anti-inflammatory drugs.
Special instructions:With rheumatoid arthritis, there is an increased amount of interleukins that cause inflammatory changes in the joints: pain, swelling, stiffness. In addition, they promote the resorption of articular surfaces.
Anakinra blocks receptors IL-1, eliminating the effect of interleukins. The drug is used in conjunction with basic drugs in the treatment of rheumatoid arthritis.
It is recommended to do subcutaneous injections at the same time of day.
In infectious diseases, the administration of the drug is canceled, after curing acute processes, injections continue until the clinical improvement of rheumatoid arthritis.